A comparative study of the efficacy of irbesartan/hydrochlorothiazide 300/25 mg versus valsartan/hydrochlorothiazide 160/25 mg using home blood pressure monitoring in the treatment of mild to moderate hypertension.

Trial Profile

A comparative study of the efficacy of irbesartan/hydrochlorothiazide 300/25 mg versus valsartan/hydrochlorothiazide 160/25 mg using home blood pressure monitoring in the treatment of mild to moderate hypertension.

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Oct 2012

At a glance

  • Drugs Irbesartan/hydrochlorothiazide (Primary) ; Valsartan/hydrochlorothiazide (Primary)
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Acronyms COSIMA-2; COSIMA-II
  • Sponsors Sanofi
  • Most Recent Events

    • 04 Oct 2012 Results presented at the 24th Scientific Meeting of the International Society of Hypertension.
    • 16 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Jul 2010 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top